Roivant Sciences (NASDAQ:ROIV) Stock Update and Phase 3 VALOR Study Results

Company Overview - Roivant Sciences (NASDAQ:ROIV) is a biopharmaceutical company focused on developing transformative medicines [1] - The company has a market capitalization of approximately $10.23 billion [5] Stock Performance - On September 18, 2025, Citigroup adjusted its rating for Roivant to Neutral, maintaining a hold action, with the stock price at $15.47 [1] - Bank of America raised its price target for Roivant from $12 to $16.50 [1] - Currently, ROIV's stock price is $14.99, reflecting a decrease of approximately 1.93% or $0.30 [4] - Over the past year, ROIV has reached a high of $16.05 and a low of $8.73 [5] - Today's trading volume for ROIV is 2,323,718 shares, indicating active investor interest [5] Clinical Study Results - Roivant announced positive results from its Phase 3 VALOR study, which evaluated brepocitinib for treating dermatomyositis (DM) [2][6] - The study showed that a 30 mg daily dose of brepocitinib led to significant improvements compared to a placebo, achieving a week 52 mean Total Improvement Score (TIS) of 46.5 versus 31.2 for the placebo group [3] - The p-value of 0.0006 indicates strong statistical significance, with more than two-thirds of patients on the 30 mg dose experiencing at least a moderate response, and nearly half achieving a major response [3] Future Plans - Roivant plans to file a New Drug Application (NDA) in the first half of 2026, following the consistent safety profile of brepocitinib [4][6] - The company will also host an investor call to discuss the findings from the VALOR study [4]